Bioprocessing, Bioengineering and Process Chemistry in the Biopharmaceutical Industry: Using Chemistry and Bioengineering to Improve the Performance of Biologics

About

Kumar Gadamasetti is currently the founder-CEO of Certum Bio located in the San Francisco Bay area in CA-USA. Current interests are in the area of small molecules as well as biologics including Antibody Drug Conjugates (ADCs) building blocks of DNA and expanded genetic alphabet repurposing existing drugs and process chemistry related to biologics and small molecules. His professional career began at Bristol-Myers Squibb Co followed by Amgen Discovery Partners International X-Mine. He was the founder of Delphian Pharmaceuticals and Certum LLC. He obtained his Ph.D. (1987) from the University of Vermont in organic chemistry of cancer drugs and precursors and has done post-doctoral work at the University of Virginia. He was the founder-chairman (2002-2004) of ACS Prospectives Process Chemistry in the Pharmaceutical Industry. He was the editor of two volumes titled Process Chemistry in the Pharmaceutical Industry (ISBN# 0-8247-1981-6 1999) and Process Chemistry in the Pharmaceutical Industry: Challenges in an Ever-Changing Climate (ISBN#13:978-0-8493-9051-7 2007). Kumar has been a visiting professor at Catholic University at Louvain Brussels Belgium and the Univ. of Pittsburgh PA-USA and was the invited speaker at Humboldt University Berlin Germany. His major accomplishments include his contributions on the development of drug substance (API) and the drug product that helped along with the respective team members in launching three products to marketing: 1. Paclitaxel® (Bristol-Myers Squibb) 2. Sensipar® (Amgen) and 3. Duexis® (Horizon Therapeutics). Stephen A. Kolodziej is an Associate Research Fellow in the Biotherapeutics Pharmaceutical Sciences division of Pfizer at the Chesterfield Missouri site. His group develops downstream manufacturing processes for biotherapeutic drug and vaccine candidates specializing in protein conjugates. He made major contributions to process and product understanding on many late-stage bacterial vaccine projects leading to the commercialization of Prevnar 20® and Penbraya®. He started his professional career as a medicinal chemist in Searle Pharmacia and then Pfizer developing novel small molecule candidates for the treatment of inflammation cancer and cardiovascular disease. He applied the tools of combinatorial chemistry to produce small libraries of candidates for evaluation in numerous preclinical programs and was a coinventor for Xalkori® an ALK inhibitor approved for the treatment of non-small cell lung cancer. Steve has a BA and a PhD in Organic Chemistry from the University of Missouri-St. Louis with Professor Rudolph E. K. Winter on the synthesis of natural products.